BACKGROUND: Little is known about the impact of sleep disturbances (SD) or sleep-related impairment (SRI) in adults with AD or their relationship with severity of AD and itch and other predictors. OBJECTIVE: The aim of this study was to determine the relationship between AD severity, SD, and SRI. METHODS: We conducted a prospective online questionnaire-based study of 287 adults with AD, including assessment of AD severity by Patient-Oriented Eczema Measure, self-reported global AD severity, Self-Assessed Eczema Area and Severity Index and visual analog scale-itch, Patient-Reported Outcome Measurement Information System SD and SRI individual items, and T scores. RESULTS: Adults with AD commonly endorsed all SD and SRI symptoms examined; only 58 (21.8%) reported having good or very good sleep quality in the past week. However, only a minority of adults with AD endorsed a more profound impact from these individual aspects of SD and SRI in the past week or Patient-Reported Outcome Measurement Information System T scores greater than 55. In particular, SD and SRI were associated with severe or very severe AD (Patient-Oriented Eczema Measure, self-reported severity, visual analog scale-itch, and/or Self-Assessed Eczema Area and Severity Index). Sleep-related impairment was also associated with comorbid hay fever and/or anxiety. CONCLUSIONS: This study suggests that SD and SRI are common in adults with AD, particularly those with severe diseases. Sleep disturbances and SRI should be considered when assessing burden of AD and therapeutic decisions.
BACKGROUND: Little is known about the impact of sleep disturbances (SD) or sleep-related impairment (SRI) in adults with AD or their relationship with severity of AD and itch and other predictors. OBJECTIVE: The aim of this study was to determine the relationship between AD severity, SD, and SRI. METHODS: We conducted a prospective online questionnaire-based study of 287 adults with AD, including assessment of AD severity by Patient-Oriented Eczema Measure, self-reported global AD severity, Self-Assessed Eczema Area and Severity Index and visual analog scale-itch, Patient-Reported Outcome Measurement Information System SD and SRI individual items, and T scores. RESULTS: Adults with AD commonly endorsed all SD and SRI symptoms examined; only 58 (21.8%) reported having good or very good sleep quality in the past week. However, only a minority of adults with AD endorsed a more profound impact from these individual aspects of SD and SRI in the past week or Patient-Reported Outcome Measurement Information System T scores greater than 55. In particular, SD and SRI were associated with severe or very severe AD (Patient-Oriented Eczema Measure, self-reported severity, visual analog scale-itch, and/or Self-Assessed Eczema Area and Severity Index). Sleep-related impairment was also associated with comorbid hay fever and/or anxiety. CONCLUSIONS: This study suggests that SD and SRI are common in adults with AD, particularly those with severe diseases. Sleep disturbances and SRI should be considered when assessing burden of AD and therapeutic decisions.
Authors: Daniel J Buysse; Lan Yu; Douglas E Moul; Anne Germain; Angela Stover; Nathan E Dodds; Kelly L Johnston; Melissa A Shablesky-Cade; Paul A Pilkonis Journal: Sleep Date: 2010-06 Impact factor: 5.849
Authors: P P Vakharia; R Chopra; R Sacotte; N Patel; S Immaneni; T White; R Kantor; D Y Hsu; J I Silverberg Journal: Allergy Date: 2017-10-09 Impact factor: 13.146
Authors: Eric L Simpson; Marjolein Bruin-Weller; Carsten Flohr; Michael R Ardern-Jones; Sebastien Barbarot; Mette Deleuran; Thomas Bieber; Christian Vestergaard; Sara J Brown; Michael J Cork; Aaron M Drucker; Lawrence F Eichenfield; Regina Foelster-Holst; Emma Guttman-Yassky; Audrey Nosbaum; Nick J Reynolds; Jonathan I Silverberg; Jochen Schmitt; Marieke M B Seyger; Phyllis I Spuls; Jean-Francois Stalder; John C Su; Roberto Takaoka; Claudia Traidl-Hoffmann; Jacob P Thyssen; Jorien van der Schaft; Andreas Wollenberg; Alan D Irvine; Amy S Paller Journal: J Am Acad Dermatol Date: 2017-08-10 Impact factor: 11.527
Authors: Paula Kage; Laura Poblotzki; Samira Zeynalova; Julia Zarnowski; Jan-Christoph Simon; Regina Treudler Journal: Int Arch Allergy Immunol Date: 2021-12-03 Impact factor: 3.767
Authors: Anna B Fishbein; Brian T Cheng; Caroline C Tilley; Wendy Smith Begolka; Adam C Carle; Christopher B Forrest; Phillis C Zee; Amy S Paller; James W Griffith Journal: J Allergy Clin Immunol Pract Date: 2021-05-12
Authors: Naomi D Harvey; Peter J Craigon; Stephen C Shaw; Sarah C Blott; Gary C W England Journal: Animals (Basel) Date: 2019-10-16 Impact factor: 2.752